• Save €2.50


  • EG SpA
  • 025869013
Lenirit dermatological cream thanks to the action of hydrocortisone is indicated in the treatment of insect bites, irritation, redness, itching, dermatitis and eczema. Lenirit cream is an over-the-counter drug that can be purchased without a prescription.

info_outline View product sheet
Final Price €8.50
Regular Price €11.00
Save €2.50
check_circle Available (9 Items)
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Other products Others products at unbeatable price


Therapeutic indications

Insect bites, itching, localized rashes or burns, eczema.

Dosage and method of use

Rubbing lightly, spread the cream on the affected part in a thin layer, twice a day. Do not exceed the recommended dose. LENIRIT should not be used in children less than two years of age (see section 4.3).


Known hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Infections and skin diseases: tuberculosis, pyoderma, mycosis, as well as skin ulcers and wounds, skin tumors.The use of the cream is contraindicated on the skin of the face, on the anogenital area, on large lesions, infectious diseases (syphilis), viral infectious diseases (such as herpes, chicken pox), perioral dermatitis, acne, rosacea, skin reactions after vaccination, pustular psoriasis. Lenirit should not be used in infants and children under 2 years of age.

Side effects

The use, especially if prolonged, of products for topical use can give rise to phenomena of irritation or sensitization. In this case it is necessary to interrupt the treatment and institute a suitable therapy. Acne, steroid induced purpura, dry skin, hypertrichosis, skin hypopigmentation, skin atrophy and striae, telangiectasia, perioral dermatitis, folliculitis, pruritus, blurred vision may occur during application of the cream (see also section 4.4). The increased absorption due to the use of an occlusive dressing can cause systemic effects such as edema, hypertension and impaired immune system; Suppression of the hypothalamic-pituitary-adrenal axis and Cushing's syndrome may also occur, particularly in pediatric patients. Prolonged use of corticosteroids in children can cause growth and developmental disturbances (see section 4.4). Glaucoma or cataracts may occasionally occur following topical application to the eyelid area (see section 4.4).The incidence of adverse reactions is unknown. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

If conditions worsen or if symptoms persist for more than 7 days, discontinue applications and consult a doctor. Avoid contact with eyes. The use, especially if prolonged, of topical medicines can give rise to irritation or sensitization phenomena. In this case it is necessary to interrupt the treatment and institute a suitable therapy. Prolonged use of this medicine can cause telangiectasia and skin atrophy. When used for a long time, or on a large area of skin, hydrocortisone can be absorbed into the blood and exert systemic activity. This occurrence occurs more easily if the occlusive bandage is used; the diaper can act as an occlusive dressing. Systemic absorption of topical corticosteroids may result in reversible suppression of the hypothalamic-pituitary-adrenal axis with potential glucocorticosteroid insufficiency after discontinuation of treatment. Following systemic absorption of topical corticosteroids, manifestations of Cushing's syndrome, glycosuria, hyperglycemia during treatment may also occur in some patients. Patients applying a topical steroid over a large surface or in areas with occlusive dressing should be monitored periodically for suppression of the hypothalamic-pituitary-adrenal axis. Visual disturbances: Visual disturbances may be reported with the use of systemic and topical corticosteroids. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after use of systemic and topical corticosteroids. In case of use in the area adjacent to the eyes, appropriate precautions should be taken. If this happens, the cream residue should be rinsed off with water. The cream contains ethyl parahydroxybenzoate, methyl parahydroxybenzoate and propyl parahydroxybenzoate which can cause allergic reactions (even delayed).Pediatric population: Do not use in infants and children under 2 years of age (see section 4.3). Particular caution is recommended when using the medicinal product in children due to the risk of systemic exposure to hydrocortisone. Because the body surface area to body weight ratio in children is higher than in adults, children are more at risk of systemic corticosteroid effects, including suppression of the hypothalamus-pituitary-adrenal axis and Cushing's syndrome, than in adults. Prolonged use of corticosteroids in children can cause growth and developmental disturbances. The duration of treatment should be as short as possible and the lowest dose should be used. The growth and development of the child should be monitored (see section 4.4).Use in elderly patients: Elderly people may experience more pronounced side effects, especially in co-morbid cases, such as osteoporosis, hypertension, hypokalaemia, diabetes mellitus, in addition to greater susceptibility to infections and reduced skin thickness. These people must be carefully monitored to avoid the occurrence of life-threatening reactions. In case of subcutaneous atrophic conditions, especially in the elderly, the medicinal product should be used with caution.Use in patients with renal or hepatic insufficiency: Special precautions for use should be used in patients with hepatic disease or renal insufficiency and frequent clinical monitoring of health is required.

Pregnancy and breastfeeding

The use of Lenirit is not recommended during pregnancy and lactation.

Expiration and retention

This medicine does not require any special storage conditions.

Interactions with other drugs

No cases of interaction and incompatibility with other medicinal products have been reported.


Cases of overdose are not known with the topical use of hydrocortisone at the concentration contained in LENIRIT (0.5%), however, avoid prolonged applications, especially on large surfaces. If high doses of the medicine are used on large areas of skin, under tight clothing or on damaged skin, the medicine may be absorbed into the blood and cause systemic corticosteroid effects (see section 4.4). In this case, a gradual suspension of treatment is recommended.

Active principles

100 g of cream contain:Active principle: hydrocortisone acetate 0.5 g.Excipients with known effects: methyl parahydroxybenzoate; ethyl parahydroxybenzoate; propyl parahydroxybenzoate. For the full list of excipients, see section 6.1.


Polyglycol ester of C12-C18 fatty acids; self-emulsifying glyceryl monodistearate; squalane; cetyl palmitate; methyl parahydroxybenzoate; ethyl parahydroxybenzoate; propyl parahydroxybenzoate; scent; purified water.

9 Items

Data sheet

0.5% dermatological cream 20 g
Product Type
ATC code
ATC description
Therapeutic Group
Active principle
hydrocortisone acetate (FU)
Pharmaceutical form
Type of Administration
1 tube
20 grams
Quantity of the Active Ingredient
Recipe required
OTC - self-medication medicine